Integrated Biopharma, Inc. INBP
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -451.73% | -231.90% | -122.20% | 56.28% | 621.43% |
| Total Depreciation and Amortization | 9.38% | 6.51% | 2.38% | 2.65% | 3.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -67.38% | -3.61% | 75.87% | 158.48% | 320.90% |
| Change in Net Operating Assets | 247.07% | 229.60% | 266.29% | 68.81% | -101.88% |
| Cash from Operations | -39.90% | 134.94% | 34.99% | 843.90% | 118.98% |
| Capital Expenditure | -81.15% | 46.11% | 47.40% | 46.06% | 65.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -65.85% | 43.80% | 44.97% | 43.61% | 62.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -462.50% | -88.89% | 17.86% | 69.23% | 80.95% |
| Issuance of Common Stock | -- | 277.78% | 277.78% | -- | 561.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -157.69% | -- | 550.00% | 289.74% | 368.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -55.83% | 204.46% | 65.01% | 861.92% | 436.84% |